Idrossicarbamide Aurobindo (Hydroxycarbamide)

Hydroxycarbamide blocks the enzyme ribonucleotide reductase, which is essential for producing deoxyribonucleotides needed for DNA synthesis. By depleting these building blocks, the drug hampers DNA replication in rapidly dividing cells, leading to cell‑cycle arrest and apoptosis of malignant or abnormal hematopoietic cells.

The specific dose of Idrossicarbamide Aurobindo is determined by the prescribing clinician based on the patient’s diagnosis, disease severity, renal and hepatic function, and response to therapy. Dosing regimens are individualized and should follow the prescriber’s instructions.

Hydroxycarbamide is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It is contraindicated in pregnancy and should not be used by breastfeeding mothers because it can be excreted in milk. Effective contraception is required for both men and women of reproductive potential.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Hydroxycarbamide is a small‑molecule oral agent that directly inhibits ribonucleotide reductase, whereas many alternatives such as tyrosine‑kinase inhibitors (e.g., imatinib) target specific signalling pathways. Hydroxycarbamide is often chosen for its oral convenience, cost‑effectiveness, and proven efficacy in certain myeloproliferative disorders, but the choice depends on disease specifics and patient tolerance.

Idrossicarbamide Aurobindo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

The medication is taken orally, usually with a full glass of water. It may be administered with or without food, but patients should follow the prescriber’s guidance regarding timing and any dietary considerations to optimise absorption and minimise gastrointestinal discomfort.

The most serious risks include severe bone‑marrow suppression leading to pancytopenia, renal or hepatic toxicity, life‑threatening skin reactions such as Stevens‑Johnson syndrome, leg ulcers, and the potential for secondary malignancies. Regular monitoring of blood counts and organ function is essential to detect these complications early.

Patients with known hypersensitivity to hydroxycarbamide, those who are pregnant or planning pregnancy without effective contraception, individuals with severe renal or hepatic impairment, and patients receiving other potent myelosuppressive therapies should avoid using Idrossicarbamide Aurobindo unless specifically directed by a qualified healthcare professional.